ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease von Ledermann, J.A., Matias-Guiu, X., Amant, F., Concin, N., Davidson, B., Fotopoulou, C., González-Martin, A., Gourley, C., Leary, A., Lorusso, D., Banerjee, S., Chiva, L., Cibula, D., Colombo, N., Croce, S., Eriksson, A.G., Falandry, C., Fischerova, D., Harter, P., Joly, F., Lazaro, C., Lok, C., Mahner, S., Marmé, F., Marth, C., McCluggage, W.G., McNeish, I.A., Morice, P., Nicum, S., Oaknin, A., Pérez-Fidalgo, J.A., Pignata, S., Ramirez, P.T., Ray-Coquard, I., Romero, I., Scambia, G., Sehouli, J., Shapira-Frommer, R., Sundar, S., Tan, D.S.P., Taskiran, C., van Driel, W.J., Vergote, I., Planchamp, F., Sessa, C., Fagotti, A.

Volltext

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib von Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., Friedlander, M., Gourley, C., Plummer, R., Rustin, G., Sessa, C., Leunen, K., Ledermann, J., Swaisland, H., Fielding, A., Bannister, W., Nicum, S., Molife, L. R.

Volltext

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer von Hall, M.R., Dehbi, H.-M., Banerjee, S., Lord, R., Clamp, A., Ledermann, J.A., Nicum, S., Lilleywhite, R., Bowen, R., Michael, A., Feeney, A., Glasspool, R., Hackshaw, A., Rustin, G.

Volltext

Real World Outcomes in Patients With Recurrent, Advanced, or Metastatic Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab von Pawsey, A., Mahalingam, P., Senthivel, N., Ramessur, A., Turnbull, E., Usman, S., Browne, R., Patel, A., Stewart, A., Tookman, L., Counsell, N., Miller, R., Nicum, S., Eminowicz, G.

Volltext

OVPSYCH2: A randomized controlled trial of psychological support versus standard of care following chemotherapy for ovarian cancer von Frangou, E., Bertelli, G., Love, S., Mackean, M.J., Glasspool, R.M., Fotopoulou, C., Cook, A., Nicum, S., Lord, R., Ferguson, M., Roux, R.L., Martinez, M., Butcher, C., Hulbert-Williams, N., Howells, L., Blagden, S.P.

Volltext

OVPSYCH2: A randomised study of psychological support versus standard of care following chemotherapy for ovarian cancer von Blagden, S., Bertelli, G., Frangou, E., Butcher, C., Love, S., Mackean, M., Glasspool, R.M., Cook, A., Nicum, S., Lord, R., Ferguson, M., Roux, R.L., Martinez, M., Black, S., James, A., Palmer, H., Hughes, S., Marriott, C., Howells, L.

Volltext

2761 Phase II clinical trial of 6 mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours von Nicum, S, Boyle, L, Strauss, V, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Roberts, C

Volltext

817P A systematic review of recruitment of ethnic minorities to RCTs of systemic anti-cancer therapies in gynaecological cancers von Steventon, L., Man, K., Chambers, P., Nicum, S., Wei, L.

Volltext

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease von Colombo, N, Sessa, C, du Bois, A, Ledermann, J, McCluggage, W G, McNeish, I, Morice, P, Pignata, S, Ray-Coquard, I, Vergote, I, Baert, T, Belaroussi, I, Dashora, A, Olbrecht, S, Planchamp, F, Querleu, D

Volltext

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer von Moore, Kathleen N, Angelergues, Antoine, Konecny, Gottfried E, García, Yolanda, Banerjee, Susana, Lorusso, Domenica, Lee, Jung-Yun, Moroney, John W, Colombo, Nicoletta, Roszak, Andrzej, Tromp, Jacqueline, Myers, Tashanna, Lee, Jeong-Won, Beiner, Mario, Cosgrove, Casey M, Cibula, David, Martin, Lainie P, Sabatier, Renaud, Buscema, Joseph, Estévez-García, Purificación, Coffman, Lan, Nicum, Shibani, Duska, Linda R, Pignata, Sandro, Gálvez, Fernando, Wang, Yuemei, Method, Michael, Berkenblit, Anna, Bello Roufai, Diana, Van Gorp, Toon

Volltext

250P The impact of inter-cycle treatment delays on progression-free survival in early stage breast cancer von Steventon, L., Kipps, E., Man, K., Forster, M.D., Wong, I., Shah, S., Miller, R., Nicum, S., Almossawi, O., Chambers, P.

Volltext

LBA33 ICON9: International phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platin... von Nicum, S., Ledermann, J.A., Mileshkin, L., Jayson, G.C., Gourley, C., Michael, A., Lord, R., Mackay, H., Hall, M., Tookman, L., Banerjee, S., Harnett, P., Macdonald, I., Lee, Y.C., Elyashiv, O., Wilkinson, K., Farrelly, L., Counsell, N.

Volltext

600P Ethnic and socio-economic status in ovarian cancer patients recruited to clinical trials von Palmer, K.R., El-Shakankery, K.H., Kefas, J., Gao, K., Crusz, S., Flynn, M., Jonathan, L., Lockley, M., McCormack, M., Macdonald, N., Nicum, S., Devlin, M-J., Miller, R.

Volltext

575P Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade serous or endometrioid ovarian cancer: A multi-national observational study von Morgan, R.D., Clamp, A.R., Barnes, B., Schlecht, H., Yarram-Smith, L., Wallis, Y., Morgan, S., Valganon, M., Hudson, E., McKenna, S., Sundar, S., Nicum, S., Brenton, J.D., Kristeleit, R., Banerjee, S., McNeish, I., Ledermann, J.A., Taylor, S., Evans, G., Jayson, G.C.

Volltext

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer von Moore, K.N, Angelergues, A, Konecny, G.E, Garcia, Y, Banerjee, S, Lorusso, D, Lee, J.-Y, Moroney, J.W, Colombo, N, Roszak, A, Tromp, J, Myers, T, Lee, J.-W, Beiner, M, Cosgrove, C.M, Cibula, D, Martin, L.P, Sabatier, R, Buscema, J, Estevez-Garcia, P, Coffman, L, Nicum, S, Duska, L.R, Pignata, S, Galvez, F, Wang, Y, Method, M, Berkenblit, A, Roufai, D. Bello, Van Gorp, T

Volltext

A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC) von Michael, A, Wilson, W, Sunshine, S, Annels, N, Harrop, R, Blount, D, Pandha, H, Lord, R, Ngai, Y, Nicum, S, Stylianou, L, Gwyther, S, McNeish, IA, Hackshaw, A, Ledermann, J

Volltext

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup von Gonzalez-Martin, Antonio, Lorusso, Domenica, Gourley, Charlie, Mirza, Mansoor Raza, Kurtz, Jean-Emmanuel, Moore, Kathleen, Kridelka, Frédéric, McNeish, Iain, Reuss, Alexander, du Bois, Andreas, Mahner, Sven, Ray-Coquard, Isabelle, Kohn, Elise C, Berek, Jonathan S, Tan, David S P, Colombo, Nicoletta, Zang, Rongyu, Concin, Nicole, Herrington, C Simon, Marth, Christian, Poveda, Andres, Fujiwara, Keiichi, Stuart, Gavin C E, Oza, Amit M, Bookman, Michael A, Mahner, Sven, Reuss, Alexander, du Bois, Andreas, Grimm, Christoph, Berger, Regina, Concin, Nicole, Chang, Ting-Chang, Ochiai, Kazunori, Gebski, Val, Davis, Alison, Beale, Philip, Kridelka, Frédéric, Denys, Hannelore, Vandecaveye, Vincent, Del Pilar Estevez Diz, Maria, Stuart, Gavin, MacKay, Helen, Carey, Mark, Cibula, David, Dundr (path), Pavel, Dorigo, Oliver, Berek, Jonathan, O'Donnell, Dearbhaile, Saadeh, Abu, Boere, Ingrid, Lok, Christianne, Coronado, Pluvio, Ottevanger, Nelleke, Tan, David SP, Ng, Joseph, Gonzalez Martin, Antonio, Oaknin, Ana, Poveda, Andres, Perez Fidalgo, Alejandro, Rauh-Hain, Alejandro, Lu, Karen, López-Zavala, Carlos, Gómez-García, Eva María, Ray-Coquard, Isabelle, Kurtz, Jean-Emmanuel, Joly, Florence, Votan, Bénédicte, Bookman, Michael, Moore, Kathleen, Arend, Rebecca, Fujiwara, Keiichi, Fujiwara, Hiroyuki, Hasegawa, Kosei, Tsoref, Dalia, Oda, Katsutoshi, Okamoto, Aikou, Michel, Dayana, Kim, Hee-Seung, Lee, Jung-Yun, Mukhopadhyay, Asima, Katsaros, Dionyssios, Colombo, Nicoletta, Pignata, Sandro, Lorusso, Domenica, Kohn, Elise, Lee, Jung-Min, McNeish, Iain, Nicum, Shibani, Farrelly, Laura, Sehouli, Jalid, Keller, Maren, Braicu, Elena, Bjørge, Line, Mirza, Mansoor Raza, Auranen, Annika, Welch, Stephen, Heinzelmann, Viola, Herrington, C Simon, Zang, Rongyu, Zhu, Jianqing

Volltext

722O Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA) von Nicum, S., Holmes, J., McGregor, N., Dunn, R., Collins, L., Kaye, S., McNeish, I., Glasspool, R.M., Hall, M., Roux, R., Michael, A., Banerjee, S., Kristeleit, R., Jayson, G., Clamp, A., Mansouri, A.

Volltext

British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: recommendations for practice update 2024 von Moss, E, Taylor, A, Andreou, A, Ang, C, Arora, R, Attygalle, A, Banerjee, S, Bowen, R, Buckley, L, Burbos, N, Coleridge, S, Edmondson, R, El-Bahrawy, M, Fotopoulou, C, Frost, J, Ganesan, R, George, A, Hanna, L, Kaur, B, Manchanda, R, Maxwell, H, Michael, A, Miles, T, Newton, C, Nicum, S, Ratnavelu, N, Ryan, N, Sundar, S, Vroobel, K, Walther, A, Wong, J, Morrison, J

Volltext

OCTOVA: A randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with BRCA-mutated platinum-resistant ovarian cancer von Nicum, S., Strauss, V.Y., McGregor, N., McNeish, I., Roux, R., Hall, M., Michael, A., Roberts, C.

Volltext